Somatic Marker Theory-Based Integrated Model of Bottom-up Psychosomatic Symptom Formation from Body to Symptoms
Advances in Educational Technology and Psychology · 2026 · 10 (2)
DOI: 10.23977/aetp.2026.100211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Educational Technology and Psychology, 2026.
Abstract (Originalsprache)
The mechanisms underlying the development of clinical psychosomatic symptoms have long been predominantly studied through a 'top-down' cognitive-emotional pathway. However, a large number of patients presenting with somatic discomfort as their chief complaint, which cannot be explained by organic pathology, exhibit the opposite process: abnormally amplified somatic sensations, lacking effective emotional markers, gradually solidify into persistent psychosomatic symptoms. Building upon a systematic review of somatic marking theory, interoception theory and emotional construction theory, this paper proposes an integrative bottom-up theoretical model that divides the development of psychosomatic symptoms into four stages: perceptual abnormality, marking deficiency, integrative dysfunction and symptom consolidation. Finally, the practical implications of the model are discussed in terms of clinical differentiation, doctor-patient communication and psychotherapeutic strategies.
Zitieren
APA
(2026). Somatic Marker Theory-Based Integrated Model of Bottom-up Psychosomatic Symptom Formation from Body to Symptoms. Advances in Educational Technology and Psychology, 10(2). https://doi.org/10.23977/aetp.2026.100211
Vancouver
Somatic Marker Theory-Based Integrated Model of Bottom-up Psychosomatic Symptom Formation from Body to Symptoms. Advances in Educational Technology and Psychology. 2026;10(2). doi:10.23977/aetp.2026.100211
BibTeX
@article{euvimed2026,
title = {Somatic Marker Theory-Based Integrated Model of Bottom-up Psychosomatic Symptom Formation from Body to Symptoms},
journal = {Advances in Educational Technology and Psychology},
year = {2026},
volume = {10},
number = {2},
doi = {10.23977/aetp.2026.100211}
}
EUVIMED